



WIPO

WORLD
INTELLECTUAL PROPERTY
ORGANIZATION



Patent Information

Lutz Mailänder
Head, Patent Information Section
Global IP Infrastructure Sector

Geneva
17 February
2011

Overview


- Sources of patent information (primary, secondary)
- Publication practices
- Components/categories of patent information

- Information related to individual application
- Information derived from collections

- Availability in different countries

Role of patents

- ▶ Historically two competing interests of two stakeholders:



Role of patent information

Publication of patent information serves two purposes:

- ▶ Informing of existing protection rights
what? where? when?
- ▶ Disclosure and dissemination of technical teaching

Life cycle of an individual application

- All starts with an **invention**



- Application for patent at **OFF** (**O**ffice of **F**irst **F**iling)



- Subsequent applications at **OSFs** (**O**ffice of **S**econd **F**iling)


- claiming priority (Paris convention) **Legal family**

- > OSF recognizes application date of OFF (priority date)

- **not** claiming priority **Technical family**

- > often not the case in DCs

Stages of patent prosecution



During all these stages patent information is constantly added by

- OFF
- OFS
- third parties

What is **published** over life cycle ?

- Varies strongly from country to country
- Minimum: notification of grants or other events in Gazettes
 - if so: further information only retrievable through file inspection
- Often but not always:
 - full specification of granted patents
 - applications
 - usually 18 month after filing
 - many countries (DCs) don't (PCT NPE)
 - search reports, corrections, amendments, translations
 - legal status

What is published over life cycle ?

Conclusion:

- In (many)(some) countries the public life of an application only starts after granting
- In (many)(some) countries only file inspection discloses technical teaching and scope of protection

Primary patent information sources

▶ Each jurisdiction defines the publication of authoritative patent information and the respective authority

▶ Traditionally, three publication products can be distinguished:

- National (Patent) Gazette

- Publications of full patent applications, granted patents

- National Patent Registers

Gazettes

- publication of notifications, e.g. fee change
- publication of essential legal events, such as grants
- **only (some) bibliographic data** (front page)
- limited technical disclosure (sometimes abstract)
- limited legal information (usually no claims)
- regularly published gazette editions
- published editions are not updated
- changes/corrections appear in new edition
- often dedicated IP right gazettes
- sometimes general government gazette

Publication of full specifications

- complement the limited information in Gazettes
- serve for full technical disclosure
- claims define
 - potential protection (publication of applications)
 - granted protection (publication of granted patents)

Components of a patent documents

- ▶ Bibliographic data (frontpage)
 - title, applicant(s), inventor(s), filing date, priorities,..
- ▶ Description part
 - problem to be solved, prior art, inventive idea, embodiments
- ▶ Drawings
- ▶ Claims
- ▶ (State of art search report)

EP



Description

View this page in: [English](#) ▼

[Translate](#)

[Turn off for: Detect language](#)

such as simvastatin and lovastatin, antihyperlipidemic efficacy in HIV-infected patients on protease inhibitor therapy may be compromised at standard statin doses.

SUMMARY OF THE INVENTION

In one aspect, there is provided by the present invention a method for reducing elevated plasma LDL-cholesterol and/or triglyceride levels in an HIV-infected patient undergoing therapy with one or more HIV protease inhibitors resulting in such elevated LDL-cholesterol and/or triglyceride levels, comprising substituting in such therapy an HIV-inhibiting and LDL-cholesterol and/or triglyceride reducing amount of atazanavir for the offending HIV protease inhibitor. The reduction in hyperlipidemia is similar to that achieved by use of a statin, but without the side effects seen with this class of lipid-lowering agents. In another aspect, there is provided a method for reducing elevated plasma LDL-cholesterol and/or triglyceride levels in an HIV-infected patient undergoing HIV protease inhibitor therapy which comprises administering to said patient an effective HIV-inhibiting amount of atazanavir in combination with an HIV-inhibiting amount of at least one other HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase. In yet another aspect, there is provided a method for treating HIV infection in a patient exhibiting elevated plasma LDL-cholesterol and/or triglyceride levels comprising administering to said patient an HIV-inhibiting amount of atazanavir.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the unexpected observation that atazanavir, unlike other HIV protease inhibitors, has no significant effect on plasma LDL-cholesterol and triglyceride levels when administered in normal HIV-inhibiting dosages.

In clinical studies carried out on 98 HIV-positive patients who have taken atazanavir for one year, no increases in plasma LDL-cholesterol or triglycerides were observed. Thus, atazanavir is particularly useful in the treatment of HIV-positive patients who have elevated plasma LDL-cholesterol and/or triglyceride levels. It can be used as monotherapy or as part of a "cocktail" which would include other antiretroviral drugs such as reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and other HIV protease inhibitors. In one aspect, then, the present invention provides a method for treating HIV infection in a patient exhibiting elevated plasma LDL-cholesterol and/or triglyceride levels comprising administering to said patient an HIV-inhibiting amount of atazanavir.

Atazanavir is especially useful in the treatment of HIV-infected patients who have elevated plasma LDL-cholesterol and/or triglyceride levels resulting from antiretroviral therapy with an HIV protease inhibitor.

In a Phase II randomized study, the safety and anti-HIV activity of three once daily doses of atazanavir (200 mg, 400 mg and 500 mg) was compared with 750 mg of the protease inhibitor, nelfinavir dosed three times daily. Twenty-one patients received nelfinavir in combination with stavudine and didanosine, while atazanavir was administered both as monotherapy (for two weeks) and then in combination with stavudine and didanosine to 78 treatment-naive (no prior anti-HIV therapy) patients with HIV viral loads >2000 copies per milliliter (c/mL). Patients in the atazanavir arms showed at least comparable reductions in viral load compared to the nelfinavir-treated patients, but displayed no changes in

Claims

1. (WO2003020206) USE OF ATAZANAVIR IN HIV THERAPY

PCT Biblio. Data

Description

Claims

National Phase

Notices

Documents

Note: Text based on automatic Optical Character Recognition processes.
Please use the PDF version for legal matters

Select Language 

Powered by 

CLAIMS

What is claimed is:

1. A method for reducing elevated plasma LDL and/or triglyceride levels in an HIV-infected patient resulting from therapy with one or more HIV protease inhibitors, comprising substituting an HIV-inhibiting and LDL and/or triglyceride reducing amount of atazanavir for the offending HIV protease inhibitor used in such therapy.
2. A method for reducing elevated plasma LDL and/or triglyceride levels in an HIV-infected patient undergoing HIV protease therapy which comprises administering to said patient an effective HIV-inhibiting amount of atazanavir in combination with an HIV-inhibiting amount of at least one HIV protease inhibitor metabolized by cytochrome P450 monooxygenase.
3. The method of Claim 2 wherein atazanavir is administered in combination with an HIV protease inhibitor selected from saquinavir, indinavir, amprenavir, nelfinavir, tipranavir or lopinavir.
4. The method of Claim 3 wherein atazanavir is administered in combination with saquinavir.
5. A method for treating HIV infection in a patient exhibiting elevated plasma LDL-cholesterol and/or triglyceride levels comprising administering to said patient an HIV-inhibiting amount of atazanavir.

Patent registers

- up-to-date legal status information
- varying detailedness data content
- regularly updated (often daily)
- > tomorrow

Means of publication

- Traditionally in paper (several countries still do)
- Electronically:
 - on media like CDs, DVDs
 - on dedicated websites:
 - display
 - download (single, bulk, web services)
 - as PDF, HTML, ..

Secondary sources of patent Information

- ▶ Collect data from primary sources and publish:
 - Commercial patent databases
 - Free-of-charge patent databases:
 - **hosted by some IPOs**
 - hosted by others: Google Patents, Patentlens,...

Common features and differences

- Country coverage
- Patent information retrievable
- Patent information searchable (search fields)
- Complexity of query language and search queries:
 - operators
 - truncations
 - nesting, ranges
 - weighing, fuzzyness
- Various formats e.g. for priority data,...

Major free patent databases

- Patentscope: WIPO

<http://www.wipo.int/patentscope/search/en/search.jsf>

- Espacenet: European Patent Office (EPO)

<http://ep.espacenet.com/>

- Depatisnet: German Patent Office (DPMA)

<http://depatisnet.dpma.de>

Common features **and** differences

- Search modes:

- "quick" (Espacenet), "simple" (Patentscope)

- "advanced" ([Espacenet](#)), "beginner" ([Depatisnet](#)),
"field combinations" ([Patentscope](#))

- "expert" (Depatisnet), "advanced" (Patentscope)

Espacenet

EP

- Broad country coverage (90+ countries)
- INPADOC family information
- INPADOC legal status (45+ countries)
- ECLA classifications searchable
- Limited number of search fields:
 - e.g. no full text search of keywords (only in title, abstract)
- Limited query complexity
- Machine translation of retrieved full text
- Download of result list

Quick Search

Advanced Search

Number Search

Last result list

My patents list 0

Classification Search

Get assistance ↻

Quick Help

- » How many terms can I enter per field?
- » Can I search with a combination of words?
- » Can I use truncation or wildcards?
- » How do I enter publication, application, priority and NPL reference numbers?
- » What is the difference between the IPC and the ECLA?
- » Can I enter a date range?

Advanced Search

1. Database

Select patent database:

Worldwide - full collection of published patent applications from 80+ countries

2. Search terms

Enter keywords in English - ctrl-enter expands the field you are in

Keyword(s) in title: plastic and bicycle

Keyword(s) in title or abstract: hair

Publication number: W02008014520

Application number: DE19971031696

Priority number: W01995US15925

Publication date: yyyyymmdd

Applicant(s): Institut Pasteur

Inventor(s): Smith

European Classification (ECLA): F03G7/10

Search of keywords only in title and abstract



Patentscope

- Country coverage: PCT + national collections (DCs)
- Very broad range of search fields
 - e.g. PCT full text search
- Very complex search queries
- Cross language search (CLIR)
- Google translation interface
- Visualization of statistical analysis of search results
- Filtering and relevance ranking of result list

Search | Browse | Options | News | **Help**

Simple
Advanced Search
Field Combination
Cross Lingual Expansion

Search for

Language Stem

Office

<input type="checkbox"/> PCT	<input type="checkbox"/> Guatemala	<input type="checkbox"/> Republic of Korea	<input type="checkbox"/> ARIPO
<input type="checkbox"/> Argentina	<input type="checkbox"/> Israel	<input type="checkbox"/> Singapore	<input type="checkbox"/> EPO
<input type="checkbox"/> Brazil	<input type="checkbox"/> Mexico	<input type="checkbox"/> South Africa	<input checked="" type="checkbox"/> All
<input type="checkbox"/> Colombia	<input type="checkbox"/> Morocco	<input type="checkbox"/> Spain	
<input type="checkbox"/> Costa Rica	<input type="checkbox"/> Panama	<input type="checkbox"/> Uruguay	
<input type="checkbox"/> Cuba	<input type="checkbox"/> Peru	<input type="checkbox"/> Viet Nam	

Tooltip Help

Depatisnet

- Broad country coverage (90+ countries)
- INPADOC family information
- ECLA classifications searchable
- Reclassification by DE examiners searchable ("ICP" field)
- Very broad range of search fields
 - e.g. some full text search
- Complex search queries
- Enhanced premium interface (batch download, saving of queries; requires registration)
- no machine translation, no cross language search

Search IPC

Beginner Expert Ikofax Family PIZ support

> DEPATISnet-Home > Search > Expert

Expert search

For more information please see the [Help](#) pages of the Expert search.

Formulate search

Search query:

Available fields and wildcards

Publication data

- Publication number (PN)
- Country of publication (PC)
- Publication date (PUB)
- Publication year (PY)
- Applicant/Owner (PA)
- Inventor (IN)
- Kind code (PCOD)

Text fields

- Title (TI)
- Abstract (AB)
- Description (DE)
- Claims (CL)
- Full text data (BI)

Application data

- Application number (AN)
- Country of application (AC)
- Application date (AD)
- Application year (AY)

Priority data

- Priority number (PRN)
- Country of priority (PRC)
- Priority date (PRD)
- Priority year (PRY)

? No character or any number of characters

! One character only

One or no character

= (W) (NOTW) (#W) (#A) (P) (L) (A)

Search results: 0

Sort by: Title Inventor Applicant/Owner Publication date

Search file IPC IPC main class

Order: ascending

Searching primary sources ?

▶ Free primary sources may offer additional advantages despite limited country coverage, eg

- USPTO: PatFT, AppFT

US

- US classification searchable

- US full text searchable

- JPO: IPDL

JP


- JP FI and F-term classification searchable

Commercial providers

- Commercial database providers:
Thomson, Questel, LexisNexis, Minesoft
- fee based
- broad coverage of searchable and retrievable data (e.g. full texts)
- valued added services, e.g.:
 - analysis and visualization tools
 - data enhancement, quality checks
 - added proprietary information, e.g. enhanced abstracts

(A61K-039/145)/IC

Distribution by date (Publication date)






(A61K-039/145)JIC

Top 50 assignees


Top 50



(A61K-039/09)/IC

Inventors top collaboration network

Collaborations between inventors



Abstract

DWPI Abstract ?

(WO2009056818A1)

Novelty

Pharmaceutical composition comprises a solid unit dosage form comprising **ritonavir** and **atazanavir** or their salts.

Detailed Description

An INDEPENDENT CLAIM is included for a method of making the pharmaceutical composition comprising: hot melt extruding the **ritonavir** to form an extrudate, then formulating the extrudate into the first layer; formulating the **atazanavir** into the second tablet layer; and combining the first and second layers to provide a single unitary multiple layer tablet formulation.

Activity

Anti-HIV.

Mechanism

Protease inhibitor; Cytochrome P450 inhibitor.

Use

The composition is useful for treating HIV or AIDS. No biological data given.

Advantage

The composition increases the treatment potency particularly against drug-resistant HIV-1 strains, without significantly raising the risk for toxicity in treatment-naive and treatment-experienced patients. The composition has greater stability, less risk of chemical interaction between different medicaments, smaller bulk and accurate dosage, and is easy to prepare.

Technology Focus

PHARMACEUTICALS - Preferred Composition: The composition is a tablet formulation comprising the **ritonavir** in the first layer of the formulation and the **atazanavir** in the second layer of the formulation; a water insoluble polymer and/or a water soluble polymer; and at least one excipient, where the excipient includes a plasticizer. Preferred Components: The polymer is present at least in the layer containing the **ritonavir**. The amount of **atazanavir** and **ritonavir** is 70-400 mg and 20-200 mg, respectively. The weight ratio of the **ritonavir** or **atazanavir** to the weight of the polymer is 1:1-1:6. Preferred Method: The layer containing the **ritonavir** is obtainable by hot melt extruding the **ritonavir** with the polymer. The **ritonavir** is mixed with the water soluble polymer and/or the water insoluble polymer prior the hot melt extrusion step. The **atazanavir** is mixed with the water soluble polymer and/or water insoluble polymer and extruded by hot melt granulation processor melt granulation process. The method comprises preparing a substantially homogeneous melt of the **ritonavir** or **atazanavir** and optionally one or more excipients, extruding the melt, and cooling the melt until it solidifies. The melt is formed at 50-200° C. In the method, the **ritonavir**, the polymer, and optionally one or more excipients are processed to form a powder blend which is transferred through the heated barrel of the extruder, where the powder blend melts and a molten solution product is formed, which is allowed to cool to form an extrudate. The method comprises processing the cooled extrudate into a desired pharmaceutical dosage form. The layer containing the **atazanavir** is prepared by direct compression or by wet granulation.

Abstract ?

The invention relates to pharmaceutical compositions containing a combination of **atazanavir** and **ritonavir**, to methods of making them, and their use in medicine.




DWPI sample

- written by experts
- covering some 45+ countries
- in English
- solution to language barrier in keyword searching
- alternative to poor quality of applicant written abstracts

Patent Databases

■ WIPO patent information brochures

<http://www.wipo.int/patentscope/en/publications/>

ACCESS TO THE WORLD OF TECHNOLOGY	FINDING TECHNOLOGY USING PATENTS	WIPO GUIDE TO USING PATENT INFORMATION
 <p>This publication is designed to familiarize users with the features of the PATENTSCOPE® search service and related resources. [PDF]</p> <p>This publication is also available in:</p> <ul style="list-style-type: none">- French [PDF]- Japanese [PDF]- Korean [PDF]- Polish [PDF]- Spanish [PDF]	 <p>This introduction to finding technology using patents provides a general overview of the information contained in patent documents and sources from which patent information can be obtained. [PDF]</p> <p>This introduction is also available in:</p> <ul style="list-style-type: none">- French [PDF]- Japanese [PDF]- Polish [PDF]- Spanish [PDF]	 <p>This guide is intended to assist users in using patent information, describing different search strategies and techniques as well as approaches for analyzing search results. [PDF]</p> <p>This guide is also available in:</p> <ul style="list-style-type: none">- French [PDF]- Spanish [PDF]

■ WIPO Guide to Technology Databases:

http://www.wipo.int/edocs/mdocs/mdocs/en/cdip_3/cdip_3_inf_2study_iii_inf_1.pdf

Example: PI services of EPO

■ Espacenet: free	secondary	EP
■ GPI - Global Patent Index: fee	secondary	EP
■ OPS - Open Patent Service: free	secondary	EP
■ EP publication server: free	primary	EP
■ Register Plus: free	primary	EP
■ Bulletin: free	primary	EP

Patents

About us

Topics

[Updates](#) [Grant procedure](#) **[Patent information](#)** [Law](#) [Appeals](#) [Learning](#)

[About patent information](#)

[Home](#) → [Patents](#) → [Patent information](#) → [European patent documents](#)

European patent documents

- [European publication server](#)
- [European Patent Bulletin](#)
- [Megafiles with sequence listings](#)
- [Euro-PCT cross-references](#)
- [Unpublished EP-A documents](#)
- [Basic definitions](#)
- [Announcements](#)

European patent documents

The **European publication server** is the official place to obtain copies of European patent documents. Other pages listed in this section deal with some special cases of European patent publications.

[European publication server](#)

The official place for obtaining copies of European patent applications, granted European patent specifications and corrected documents. New publications are loaded every week on publication day - Wednesday - at 14.00 hrs CET.

[European Patent Bulletin](#)

The European Patent Bulletin contains bibliographic data as well as data concerning the legal situation of European patent applications and patents as laid down in [Rule 143 EPC](#).

[Publication dates](#)

European patent applications and patent specifications are published every **Wednesday**. Note: Before 2007, if Wednesday of a week was a public holiday, publication day was moved to the first subsequent day that was not a holiday.

[Basic definitions](#)

Basic definitions used in reference to European patent documents.

[Announcements](#)

Latest announcements regarding European patent documents

[Megafiles with sequence listings](#)

Some European patent documents with large sequence listings, which are not available via the European publication server due to the download size. These can be obtained by writing to the EPO.

[Euro-PCT cross-references](#)

A large number of European patent applications are filed originally as PCT International applications and published by the World Intellectual Property Organization (WIPO). The EPO only re-publishes these applications if they need to be translated into one of the EPO's official languages. For all other "EuroPCT" applications, the EPO assigns an application number and provides a cross-reference to the earlier WIPO publication.

["Unpublished" EP-A documents](#)

A small number of patent applications receive a publication number, but are ultimately not published. Possible reasons include:

- application withdrawn by applicant
- erroneous publication as the formal

Print 

Publications

[See all publications](#)

[Patent Information News](#)

[See all patent information publications](#)

Free patent databases

[esp@cenet](#)

Search 60 million patent documents online

Learning area

Find [seminars](#) and other educational events offered by the EPO or consult [e-learning modules](#) online

European patent documents

[European publication server](#)

Components of Patent Information

- For each individual patent application:
 - bibliographic data
 - technical disclosure
 - legal information
 - claims
 - legal status
 - other

Bibliographic data

- traditionally the data on the front page of a patent document
- different components identified by INID codes
- serves to **identify** a patent publication, to **retrieve** it and **relate** it to other "similar" applications
 - same applicant
 - same inventor
 - same patent family
 - same technical field (classification)
- can partially change (assignee, classification,..)

Latest bibliographic data on file with the International Bureau



Pub. No.: WO/2003/020206 **International Application No.:** PCT/US2002/026675
Publication Date: 13.03.2003 **International Filing Date:** 21.08.2002
Chapter 2 Demand Filed: 14.03.2003

IPC: **A61K 31/4725** (2006.01), **A61K 31/551** (2006.01), **A61K 31/7072** (2006.01), **A61K 45/06** (2006.01)

Applicants: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US)

Inventors: **BECHTOLD, Clifford, M.**; (US)

Agent: **MORSE, David, M.**; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).
VOLLES, Warren, K.; BRISTOL-MYERS SQUIBB COMPANY, P.O. Box 4000, Princeton, NJ 08543-4000 (US)

Priority Data: 60/316,745 31.08.2001 US

Title **(EN)** USE OF ATAZANAVIR IN HIV THERAPY
(FR) UTILISATION D'ATAZANAVIR EN THERAPIE VIH

Abstract: **(EN)** A method for reducing elevated plasma LDL and/or triglyceride levels in an HIV-infected patient is disclosed. In this method, atazanavir (BMS-232632) can be used to treat HIV infection in patients exhibiting elevated plasma LDL-cholesterol and/or triglyceride levels, can be substituted for an offending HIV protease inhibitor used in such therapy, or can be used in combination with an HIV protease inhibitor metabolized by cytochrome P450 monooxygenase.
(FR) L'invention concerne un procédé de réduction de taux plasmatiques élevés de LDL et/ou de triglycérides chez un patient infecté par le VIH. Dans ce procédé, il est possible d'utiliser de l'atazanavir (BMS-232632) afin de traiter l'infection VIH chez des patients montrant des taux plasmatiques élevés de LDL et/ou de triglycérides, de le substituer à un inhibiteur de protéase de VIH délétère utilisé dans une telle thérapie, ou de l'utiliser en combinaison avec un inhibiteur de protéase de VIH métabolisé par une monooxygénase à cytochrome P450.

Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
 African Regional Intellectual Property Org. (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
 Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
 European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR)
 African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Publication Language: English (EN)
Filing Language: English (EN)

Patentscope
 Front Page
 HTML

Inid codes

PDF
Front Page

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization



Classification

(43) 5 July 2007 (05.07.2007)

(10) International Publication Number
WO 2007/076115 A2

Publication number

(51) International Patent Classification:
A01H 5/00 (2006.01) C12N 15/82 (2006.01)
C12N 9/10 (2006.01) C12N 5/04 (2006.01)

5727-107th Street, Edmonton, Alberta, T6G 2E9 (CA).
THEODORIS, George [US/US];
Vallejo, CA 94591 (US).

(21) International Application Number:
PCT/US2006/049241

(74) Agents: AMH, Lisa, A. et al.; Morris
425 Market Street, San Francisco, CA 94105-2482 (US).

(22) International Filing Date:
21 December 2006 (21.12.2006)

Filing date

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/753,818 23 December 2005 (23.12.2005) US

Priority data

(71) Applicant (for all designated States except US): AR-
CADIA BIOSCIENCES, INC. [US/US]; 202 Cousteau
Place, Suite 200, Davis, CA 95616 (US).

Applicant(s)

(72) Inventors; and

(75) Inventors/Applicants (for US only): KRIDL, Jean
[US/US]; 538 Reed Drive, Davis, CA 95616 (US).
DEPAUW, Mary [CA/CA]; 9508 145th Street, Edmon-
ton, Alberta, T5N 2W7 (CA). SHRAWAT, Ashok, K.
[IN/CA]; Apt. 2011, 27 Saddleback Road, Edmonton,
Alberta, T67 4M4 (CA). GOOD, Allen, G. [CA/CA];

(84) GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NITROGEN-EFFICIENT MONOCOT PLANTS

Technical disclosure

- Description
- Drawings
- (Claims)
- (Abstract)
- **technical teaching cannot be changed after filing**
- except for
 - corrections of obvious errors
 - inclusion of prior art in description
 - more precise description of the problem solved
- reason for rejection, opposition, revokation

Claims

- describe protected subject matter
- in independent (main) claim only essential features of invention
- dependent claims describe additional advantageous features
- usually **change** during examination, ie after comparison with prior art:
 - narrower scope of protection
 - more precise wording
- only features from description may be included in amended claims



Legal status data

- All data related to legal **events or actions** as defined by the respective patent law and regulations of a particular **jurisdiction**

events > data change over the lifetime of patents

jurisdiction > different definitions limit comparability

- essential for determining validity of protection
- national registers as primary sources
- > tomorrow



EPO register legal status data

Register Plus - EP02797744			
urrent security settings put your computer at risk. Click here to change your security settings...			
	Supplementary search report:	12.10.2004	
Classification	International	A61K31/7072, A61K31/551, A61P31/18	[2006/16]
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR [2004/22]		
Extension states	AL	12.03.2004	
	LT	12.03.2004	
	LV	12.03.2004	
	MK	12.03.2004	
	RO	12.03.2004	
	SI	12.03.2004	
Title	German	VERWENDUNG VON ATAZANAVIR IN DER HIV-THERAPIE	[2004/22]
	English	USE OF ATAZANAVIR IN HIV THERAPY	[2004/22]
	French	UTILISATION D'ATAZANAVIR EN THERAPIE VIH	[2004/22]
Entry into regional phase	12.03.2004	National basic fee paid	
	12.03.2004	Search fee paid	
	12.03.2004	Designation fee(s) paid	
	12.03.2004	Examination fee paid	
Examination procedure	14.03.2003	Request for preliminary examination filed International Preliminary Examining Authority: US	
	13.02.2004	Amendment by applicant (claims and/or description)	
	12.03.2004	Examination requested	
	21.10.2005	Despatch of a communication from the examining division (Time limit: MD4)	
	28.02.2006	Reply to a communication from the examining division	
	24.03.2006	Communication of intention to grant the patent	
	02.08.2006	Fee for grant paid	
	02.08.2006	Fee for printing paid	
Opposition(s)	05.07.2007	No opposition filed within time limit [2007/39]	

Other patent information

- Patent family information, ie extensions to other OSF:
- Prior art search reports
- Examination file
- Value added information (commercial providers)

Other patent information

- Patent family information, ie extensions to other OSF:
 - derived from priority claims
 - different family definitions
 - available eg via INPADOC database



Quick Search

Advanced Search

Number Search

Last result list

My patents list 0

Classification Search

Get assistance

Quick Help

- » Why are some tabs deactivated for certain documents?
- » Why does a list of documents with the heading "Also published as" sometimes appear, and what are these documents?
- » What does A1, A2, A3 and B stand for after an EP publication number in the "Also published as" list?
- » What is a cited document?
- » What are citing documents?

In my patents list | Print

[Return to result list](#)

USE OF ATAZANAVIR IN HIV THERAPY

Bibliographic data

Description

Claims

Mosaics

Original document

INPADOC legal status

Publication number: WO03020206 (A2)

Publication date: 2003-03-13

Inventor(s): BECHTOLD CLIFFORD M +

Applicant(s): SQUIBB BRISTOL MYERS CO [US] +

Classification:

- **international:** A61K31/4402; A61K31/472; A61K31/4725; A61K31/496; A61K31/551; A61K31/7072; A61K45/06; A61P3/06; A61P31/18; A61K; A61K31/4402; A61K31/472; A61K31/496; A61K31/551; A61K31/7042; A61K45/00; A61P3/00; A61P31/00; (IPC1-7): A61K

- **European:** A61K45/06; A61K31/4725; A61K31/551; A61K31/7072

Application number: WO2002US26675 20020821

Priority number(s): US20010316745P 20010831

[View INPADOC patent family](#)

[View list of citing documents](#)

[View document in the European Register](#)

Also published as:

- WO03020206 (A3)
- ZA200401412 (A)
- YU12204 (A)
- RU2316341 (C2)
- PL367873 (A1)

[more >>](#)

Cited documents:

- XP002961665 (A)
- XP002961666 (A)

[View all](#)

[Report a data error here](#)

Abstract of **WO 03020206 (A2)**

[Translate this text](#)

A method for reducing elevated plasma LDL and/or triglyceride levels in an HIV-infected patient is disclosed. In this method, atazanavir (BMS-232632) can be used to treat HIV infection in patients exhibiting elevated plasma LDL-cholesterol and/or triglyceride levels, can be substituted for an offending HIV protease inhibitor used in such therapy, or can be used in combination with an HIV protease inhibitor metabolized by cytochrome P450 monooxygenase.

Data supplied from the **espacenet** database — Worldwide



- Quick Search
- Advanced Search
- Number Search
- Last result list
- My patents list 0
- Classification Search
- Get assistance

- Quick Help**
- » What is a patent family?
 - » What is an INPADOC patent family?
 - » Are all the documents in an INPADOC family equivalents?
 - » Why is the same document published several times in the same country?

Compact | Print | Export

Return to WO03020206 (A2) | 1 2 next

page 1

Family list

26 application(s) for: **WO03020206 (A2)**

Sorting criteria: [Priority Date](#) [Inventor](#) [Applicant](#) [Ecla](#)

1	USE OF ATAZANAVIR IN HIV THERAPY	in my patents list <input type="checkbox"/>
	Inventor: BECHTOLD CLIFFORD M [US] EC: A61K45/06 ; A61K31/4725 ; (+2) Publication AT341332 (T) - 2006-10-15 info:	Applicant: SQUIBB BRISTOL MYERS CO [US] IPC: A61K31/4402 ; A61K31/472 ; A61K31/4725 ; (+18) Priority Date: 2001-08-31
2	Use of atazanavir in HIV therapy	in my patents list <input type="checkbox"/>
	Inventor: BECHTOLD CLIFFORD M EC: A61K45/06 ; A61K31/4725 ; (+2) Publication AU2002332610 (B2) - 2007-11-08 info:	Applicant: SQUIBB BRISTOL MYERS CO IPC: A61K31/4402 ; A61K31/472 ; A61K31/4725 ; (+15) Priority Date: 2001-08-31
3	USE OF ATAZANAVIR IN HIV THERAPY	in my patents list <input type="checkbox"/>
	Inventor: BECHTOLD CLIFFORD [US] EC: A61K45/06 ; A61K31/4725 ; (+2) Publication BG108585 (A) - 2005-04-30 info:	Applicant: SQUIBB BRISTOL MYERS CO [US] IPC: A61K31/4402 ; A61K31/472 ; A61K31/4725 ; (+16) Priority Date: 2001-08-31
4	USE OF ATAZANAVIR IN HIV THERAPY	in my patents list <input type="checkbox"/>
	Inventor: BECHTOLD CLIFFORD M EC: A61K45/06 ; A61K31/4725 ; (+2) Publication BR0211544 (A) - 2004-07-13 info:	Applicant: SQUIBB BRISTOL MYERS CO [US] IPC: A61K31/4402 ; A61K31/472 ; A61K31/4725 ; (+17) Priority Date: 2001-08-31
5	USE OF ATAZANAVIR IN HIV THERAPY	in my patents list <input type="checkbox"/>
	Inventor: BECHTOLD CLIFFORD M [US] EC: A61K45/06 ; A61K31/4725 ; (+2) Publication CA2458807 (A1) - 2003-03-13 info:	Applicant: SQUIBB BRISTOL MYERS CO [US] IPC: A61K31/4402 ; A61K31/472 ; A61K31/4725 ; (+17) Priority Date: 2001-08-31
6	Use of ATAZANAVIR in HIV therapy	in my patents list <input type="checkbox"/>
	Inventor: BECHTOLD CLIFFORD M [US] EC: A61K45/06 ; A61K31/4725 ; (+2) Publication CN1547476 (A) - 2004-11-17 info: CN1245988 (C) - 2006-03-22	Applicant: SQUIBB BRISTOL MYERS CO [US] IPC: A61K31/4402 ; A61K31/472 ; A61K31/4725 ; (+17) Priority Date: 2001-08-31
7	Use of atazanavir in HIV therapy	in my patents list <input type="checkbox"/>

Other patent information

- Examination file
 - communication between office and applicant
 - check examination status/prospects
 - prepare opposition
 - parts accessible through file inspection
 - online
 - manual

EPO File Inspection in register

European Patent Office

Home
Contact
Deutsch **English** Français
Legal Notices

- ⊞ About this file
- Ⓞ Legal status
- 🕒 Event history
- 📄 Citations
- 👤 Patent family
- 📁 All documents (31)
- 🔍 Search /
- examination (31)
- 📥 Received by EPO (13)
- 📥 Sent by EPO (17)
- 📥 Internal (1)

Quick Help

- » What type of documents can I view?
- » Is it possible to open a document I have found?
- » What does the number in brackets represent next to "All documents" and the categories below that section?
- » Can I open multiple documents in separate windows?
- » Is it possible to print a document?
- » Is it possible to print a list of all the documents?
- » Is it possible to download documents?

Advanced Search

SmartSearch

Search Results

Download Selected Documents

Print

Open in esp@cence®

Report data error

Help

Search

SmartSearch:

Open recent

	Date	Document type	Procedure	Number of pages
<input type="checkbox"/>	08.08.2007	Communication regarding the expiry of opposition period	Search / examination	1
<input type="checkbox"/>	07.09.2006	Decision to grant a European patent	Search / examination	2
<input type="checkbox"/>	02.08.2006	French translation of claims	Search / examination	1
<input type="checkbox"/>	02.08.2006	German translation of the claims	Search / examination	1
<input type="checkbox"/>	02.08.2006	Filing of the translations of the claims	Search / examination	2
<input type="checkbox"/>	24.03.2006	Communication about intention to grant a European patent	Search / examination	5
<input type="checkbox"/>	24.03.2006	Bibliographic data of the European patent application	Search / examination	1
<input type="checkbox"/>	24.03.2006	Druckexemplar	Search / examination	11
<input type="checkbox"/>	08.03.2006	Intention to grant (signatures)	Search / examination	1
<input type="checkbox"/>	28.02.2006	Description	Search / examination	9
<input type="checkbox"/>	28.02.2006	Reply to communication from the Examining Division	Search / examination	2
<input type="checkbox"/>	21.10.2005	Annex to the communication	Search / examination	2
<input type="checkbox"/>	21.10.2005	Communication from the Examining Division	Search / examination	1
<input type="checkbox"/>	06.10.2005	Notice drawing attention to the payment of the renewal fee and additional fee	Search / examination	1
<input type="checkbox"/>	12.11.2004	Maintenance of the application	Search / examination	1

PCT file inspection

Covers only international phase

Search result: 1 of 1

(WO/2006/026494) SYSTEM AND METHOD FOR PRODUCING WATER

Biblio. Data | Description | Claims | National Phase | Notice | **Documents**

International Application Status

Date	Title	view	download
24.05.2010	International Application Status Report	view	download

Published International Application

Date	Title	view	download
09.03.2005	Initial Publication with ISR (A1 10/2006)	view	download
09.03.2005	Declaration	view	download

Related Documents on file at the International Bureau (more information)

Date	Title	view	download
28.02.2007	Written Opinion of the International Search Authority	view	download
28.02.2007	International Preliminary Report on Patentability Chapter II (IPEA/409)	view	download
09.03.2005	US 60/642,597 10.01.2005 (Pr. Doc.)	view	download
09.03.2005	US 60/605,326 31.08.2004 (Pr. Doc.)	view	download
09.03.2005	US 60/619,264 15.10.2004 (Pr. Doc.)	view	download

Scam Warning | RSS | Terms of use

Fertig

Collective patent information

- ▶ From collections of patent publications further information can be derived:
 - Patterns of patenting activity, e.g. statistical analysis
 - Who is doing what (e.g. top applicants, inventors) ?
 - What is filed where ?
 - Patterns of innovation
 - Innovation trends/activities
 - Diversity of technology
 - Innovation tracks
 - Collaborations
 - Business information

Aggregations of patent information

individual application



family



patent data collections



PLRs, FTOs,

▶ Each subsequent level creates new patent information that can be derived by analysing the previous aggregation

Products



more complex

less complex



Patent rights related to product

- Each patent protects only one invention
- Commercial products are protected by several distinct patent rights, e.g.
 - Active ingredient
 - Process for producing active ingredient
 - Use of active ingredient
 - Method for manufacturing tablet,.....
- Patent searches can identify only individual technologies
- Products can not be searched as such
- No obligation to disclose the involved technologies

Thank you

■ lutz.mailander@wipo.int